Eton Pharmaceuticals, Inc. Gain (Loss) on Extinguishment of Debt
Eton Pharmaceuticals, Inc. (ETON) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2024-03-14
- Eton Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- Eton Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $365.00K.
- Eton Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- Eton Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Eton Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was $365.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $365.00K derived: sum of 3 quarters · filed 2024-03-14 | $365.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $365.00K derived: sum of 2 quarters · filed 2022-11-10 | $365.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $365.00K 10-Q · filed 2022-08-11 | $365.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |